Your browser doesn't support javascript.
loading
High levels of human epididymis protein 4 mRNA and protein expression are associated with chemoresistance and a poor prognosis in pancreatic cancer.
Ohkuma, Ryotaro; Yada, Erica; Ishikawa, Shumpei; Komura, Daisuke; Kubota, Yutaro; Hamada, Kazuyuki; Horiike, Atsushi; Ishiguro, Tomoyuki; Hirasawa, Yuya; Ariizumi, Hirotsugu; Shida, Midori; Watanabe, Makoto; Onoue, Rie; Ando, Kiyohiro; Tsurutani, Junji; Yoshimura, Kiyoshi; Sasada, Tetsuro; Aoki, Takeshi; Murakami, Masahiko; Norose, Tomoko; Ohike, Nobuyuki; Takimoto, Masafumi; Kobayashi, Shinichi; Tsunoda, Takuya; Wada, Satoshi.
Afiliación
  • Ohkuma R; Department of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo 157­8577, Japan.
  • Yada E; Kanagawa Cancer Center Research Institute, Yokohama, Kanagawa 241­0815, Japan.
  • Ishikawa S; Department of Molecular Preventive Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo 113­0033, Japan.
  • Komura D; Department of Molecular Preventive Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo 113­0033, Japan.
  • Kubota Y; Department of Medicine, Division of Medical Oncology, School of Medicine, Showa University, Tokyo 157­8577, Japan.
  • Hamada K; Department of Medicine, Division of Medical Oncology, School of Medicine, Showa University, Tokyo 157­8577, Japan.
  • Horiike A; Department of Medicine, Division of Medical Oncology, School of Medicine, Showa University, Tokyo 157­8577, Japan.
  • Ishiguro T; Department of Medicine, Division of Medical Oncology, School of Medicine, Showa University, Tokyo 157­8577, Japan.
  • Hirasawa Y; Department of Medicine, Division of Medical Oncology, School of Medicine, Showa University, Tokyo 157­8577, Japan.
  • Ariizumi H; Department of Medicine, Division of Medical Oncology, School of Medicine, Showa University, Tokyo 157­8577, Japan.
  • Shida M; Department of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo 157­8577, Japan.
  • Watanabe M; Department of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo 157­8577, Japan.
  • Onoue R; Department of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo 157­8577, Japan.
  • Ando K; Department of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo 157­8577, Japan.
  • Tsurutani J; Department of Medicine, Division of Medical Oncology, School of Medicine, Showa University, Tokyo 157­8577, Japan.
  • Yoshimura K; Department of Medicine, Division of Medical Oncology, School of Medicine, Showa University, Tokyo 157­8577, Japan.
  • Sasada T; Kanagawa Cancer Center Research Institute, Yokohama, Kanagawa 241­0815, Japan.
  • Aoki T; Department of Surgery, Division of General and Gastroenterological Surgery, School of Medicine, Showa University, Tokyo 157­8577, Japan.
  • Murakami M; Department of Surgery, Division of General and Gastroenterological Surgery, School of Medicine, Showa University, Tokyo 157­8577, Japan.
  • Norose T; Department of Pathology and Laboratory Medicine, School of Medicine, Showa University, Tokyo 157­8577, Japan.
  • Ohike N; Department of Pathology and Laboratory Medicine, School of Medicine, Showa University, Tokyo 157­8577, Japan.
  • Takimoto M; Department of Pathology and Laboratory Medicine, School of Medicine, Showa University, Tokyo 157­8577, Japan.
  • Kobayashi S; Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo 157­8577, Japan.
  • Tsunoda T; Department of Medicine, Division of Medical Oncology, School of Medicine, Showa University, Tokyo 157­8577, Japan.
  • Wada S; Department of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo 157­8577, Japan.
Int J Oncol ; 58(1): 57-69, 2021 01.
Article en En | MEDLINE | ID: mdl-33367933
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Pancreáticas / Biomarcadores de Tumor / Resistencia a Antineoplásicos / Proteína 2 de Dominio del Núcleo de Cuatro Disulfuros WAP / Antineoplásicos Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Aged / Animals / Female / Humans / Male / Middle aged Idioma: En Revista: Int J Oncol Asunto de la revista: NEOPLASIAS Año: 2021 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Grecia
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Pancreáticas / Biomarcadores de Tumor / Resistencia a Antineoplásicos / Proteína 2 de Dominio del Núcleo de Cuatro Disulfuros WAP / Antineoplásicos Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Aged / Animals / Female / Humans / Male / Middle aged Idioma: En Revista: Int J Oncol Asunto de la revista: NEOPLASIAS Año: 2021 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Grecia